

## DAFTAR PUSTAKA

- Aloisio E, Colombo G, Arrigo C, Dolci A, Panteghini M. 2021. Sources and clinical significance of aspartate aminotransferase increases in COVID-19. *Clin. Chim. Acta.* 522(August):88–95.doi:10.1016/j.cca.2021.08.012.
- AlWahhab R. 2021. Hal-Hal Yang Ada Hubungan Dengan Hepatitis B Pada Penderita Dewasa Di Beberapa Lokasi Di Wilayah Indonesia. *Skripsi*.
- Andersson KL, Chung RT. 2009. Monitoring during and after antiviral therapy for Hepatitis B. *Hepatology.* 49(SUPPL. 5).doi:10.1002/hep.22899.
- Andisari HE, Rosaria I. 2021. SEORANG PENDERITA HEPATITIS B AKUT BERAT, MUTAN “PRECORE”, GENOTIP C, YANG DITERAPI DENGAN ENTECAVIR MENGALAMI KECURIGAAN SINDROMA GIANOTTI-CROSTI. *Ocean. Biomed. J.* 4(1):38–52.
- Annisa. 2019. Virus Hepatitis B di Indonesia dan risiko penularan terhadap mahasiswa kedokteran. *Anat. Med. J. Fak. Kedokt.* 2(2):66–72.
- Azer. KEMMZSA. 2024. Alanine Aminotransferase (ALT) Test.
- Broquetas T, Carrión JA. 2022. Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus. *Hepatic Med. Evid. Res.* Volume 14(July):87–100.doi:10.2147/hmer.s291976.
- Campos-Valdez M, Monroy-Ramírez HC, Armendáriz-Borunda J, Sánchez-Orozco L V. 2021. Molecular mechanisms during Hepatitis B infection and the effects of the virus variability. *Viruses.* 13(6):1–30.doi:10.3390/v13061167.
- Chang CD, Dong C, Zhao SX, Yuan XW, Zhang XX, Zhao DD, Dou Y, Nan YM. Real-world study on the efficacy and safety of first-line antiviral therapy for chronic hepatitis B. *PLoS One.* 14(11):1–13.doi:10.1371/journal.pone.0224773.
- Chien RN, Liaw YF. 2022. Current Trend in Antiviral Therapy for Chronic Hepatitis B. *Viruses.* 14(2).doi:10.3390/v14020434.
- Chua J V. 2021. Immunopathology of Chronic Hepatitis B Infection : Role of Innate and Adaptive Immune Response in Disease Progression.
- Chuang YC, Tsai KN, Ou JHJ. 2022. Pathogenicity and virulence of Hepatitis B virus. *Virulence.* 13(1):258–296.doi:10.1080/21505594.2022.2028483.
- Con D, Goodwin T, Majeed A, Roberts S, Kemp W. 2021. Comparison of 48-week efficacy of Tenofovir vs Entecavir for patients with chronic Hepatitis B: A network meta-analysis. *J. Viral Hepat.* 28(1):40–50.doi:10.1111/jvh.13400.
- Deng F, Wang Q, Wen X, Xu X, Jia L, He H, Wang X, Xie Y, Li H, Qiao L, *et al.* 2024. Association between Body Mass Index and Serum Uric Acid: mediation analysis involving liver enzymes indicators. *BMC Public Health.* 24(1):3007.doi:10.1186/s12889-024-20457-1.
- Elinav. 2005. correlation between age and ALT AST.pdf.

- Eroschenko V. 2017. *diFiore's Atlas of Histology with Functional Correlations. Twelfth Ed.* Philadelphia (PA): Wolters Kluwer Health/Lippincott Williams & Wilkins.
- Fanning GC, Zoulim F, Hou J, Bertoletti A. 2019. Therapeutic strategies for Hepatitis B virus infection: towards a cure. *Nat. Rev. Drug Discov.* 18(11):827–844.doi:10.1038/s41573-019-0037-0.
- George Boon-Bee Goh, Mangesh R. Pagadala, Jaividhya Dasarathy, Aynur Unalp-Arida, Rish K. Pai, Lisa Yerian, Amer Khiyami, Achuthan Sourianarayananane, Ruth Sargent, Carol Hawkins SD& AJM. 2014. ALT AST age.pdf.
- Giannini EG, Testa R, Savarino V. 2005. Liver enzyme alteration: A guide for clinicians. *C. Can. Med. Assoc. J.* 172(3):367–379.doi:10.1503/cmaj.1040752.
- Gozali AP. 2020. Diagnosis, Tatalaksana dan Pencegahan Hepatitis B dalam Kehamilan. *Cermin Dunia Kedokt.* 47(7):354.doi:10.55175/cdk.v47i7.598.
- Guvenir M, Arikan A. 2020. Hepatitis B virus: From diagnosis to treatment. *Polish J. Microbiol.* 69(4):391–399.doi:10.33073/PJM-2020-044.
- Hall J. 2016. *Guyton and Hall Textbook of Medical Physiology. 13th ed.* Philadelphia (PA): Elsevier Inc.
- Hann HW, Wan S, Myers RE, Hann RS, Xing J, Chen B, Yang H. 2012. Comprehensive Analysis of Common Serum Liver Enzymes as Prospective Predictors of Hepatocellular Carcinoma in HBV Patients. *PLoS One.* 7(10):6–15.doi:10.1371/journal.pone.0047687.
- Harvey RA. 2019. *Lippincott Illustrated Reviews Microbiology Ed.4th.* Philadelphia (PA): Williams & Wilkins, a Wolters Kluwer busines.
- He F, Xia Z, Wang H, Zhu J, Hu L. 2022. Clinical Efficacy and Safety of Tenofovir in the Treatment of Patients with Chronic Hepatitis B. *Evidence-based Complement. Altern. Med.* 2022.doi:10.1155/2022/1673453.
- Herrscher C, Roingard P, Blanchard E. 2020. Hepatitis B Virus Entry into Cells. *Cells.* 9(6):1–15.doi:10.3390/cells9061486.
- Hung C, Hu T, Lu S, Lee C, Chen C, Kee K, Wang J. 2015. Tenofovir versus Entecavir in Treatment of Chronic Hepatitis B Virus with Severe Acute Exacerbation. *59(6):3168–3173.doi:10.1128/AAC.00261-15.*
- Jawetz M& A, Carroll K, Hobden J, Miller S, Morse S. 2016. *Medical Microbiology. 27th ed.* Volume ke-155. New York: Mcgraw-Hill Education.
- Kalas M. Ammar, Chavez L, Leon M, Taweeseedt PT, Surani S. 2021. Abnormal liver enzymes: A review for clinicians. *World J. Hepatol.* 13(11):1688–1698.doi:10.4254/wjh.v13.i11.1688.
- Kalas M Ammar, Chavez L, Leon M, Taweeseedt PT, Surani S. 2021. Abnormal liver enzymes: A review for clinicians. :1688–1698.
- Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. 2021. APASL guidance on stopping nucleos(t)ide analogues in chronic Hepatitis B patients.

- Hepatol. Int.* 15(4):833–851.doi:10.1007/s12072-021-10223-5.
- Kayaaslan B, Guner R. 2017. Adverse effects of oral antiviral therapy in chronic Hepatitis B. *World J. Hepatol.* 9(5):227–241.doi:10.4254/wjh.v9.i5.227.
- Ke W, Liu L, Zhang C, Ye X, Gao Y, Zhou S, Yang Y. 2014. Comparison of efficacy and safety of Tenofovir and Entecavir in chronic Hepatitis B virus infection: A systematic review and meta-analysis. *PLoS One.* 9(6):1–8.doi:10.1371/journal.pone.0098865.
- Kemenkes. 2019. PEDOMAN NASIONAL PELAYANAN KEDOKTERAN TATA LAKSANA HEPATITIS B. Indonesia.
- Kim S, Lee Y, Bang SM, Bak H, Yim SY, Lee YS, Yoo YJ. 2021. Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients.
- Kramvis A. 2016. The clinical implications of Hepatitis B virus genotypes and HBeAg in pediatrics. *Rev. Med. Virol.* 26(4):285–303.doi:10.1002/rmv.1885.
- Kramvis A, Chang KM, Dandri M, Farci P, Glebe D, Hu J, Janssen HLA, Lau DTY, Penicaud C, Pollicino T, *et al.* 2022. A roadmap for serum biomarkers for Hepatitis B virus: current status and future outlook. *Nat. Rev. Gastroenterol. Hepatol.* 19(11):727–745.doi:10.1038/s41575-022-00649-z.
- Kurniawan J. 2021. Perkembangan Terapi Hepatitis B Kronis di Indonesia. *J. Penyakit Dalam Indones.* 8(3):110.doi:10.7454/jpdi.v8i3.632.
- Lala V, Zubair M. 2023. Liver Function Tests.
- Lee SW, Kim SM, Hur W, Kang BY, Lee HL, Nam H, Yoo SH, Sung PS, Kwon JH, Jang JW, *et al.* 2021. Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway. *PLoS One.* 16(12 December):1–19.doi:10.1371/journal.pone.0261067.
- Lestari A, Ariguntar T, Tyas W. 2023. Profil Pemeriksaan Hematologi dan Fungsi Hati pada Lansia dengan Sirosis Hepatis. 4(1):65–72.doi:10.24853/mujg.4.1.65-72.
- Liu Z, Que S, Xu J, Peng T. 2014. Alanine aminotransferase-old biomarker and new concept: A review. *Int. J. Med. Sci.* 11(9):925–935.doi:10.7150/ijms.8951.
- Livertox. 2020. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury Tenofovir.
- Lu LG. 2014. Antiviral therapy of liver cirrhosis related to Hepatitis B virus infection. *J. Clin. Transl. Hepatol.* 2(3):197–201.doi:10.14218/JCTH.2014.00022.
- Mehta P, Reddivari AKR. 2022. Hepatitis.
- Meng JP, Luo P, Bai Y, Cui F. 2020. Entecavir downregulates interleukin-37 in patients with chronic active Hepatitis B infection. *J. Int. Med. Res.* 48(1).doi:10.1177/0300060519884157.
- Moriles K, Zubai M, Azer S. 2024. Alanine Aminotransferase (ALT) Test.
- Muljono DH. 2017. Epidemiology of Hepatitis B and C in Republic of Indonesia.

*Indian J. Forensic Med. Toxicol.* 14(2):492–494.doi:10.37506/ijfmt.v14i2.2851.

- Najmi A, Singhai A, Kaore S, Chaurasia JK, Khasbage S, Mishra A, Kushwaha S. 2023. Evaluation of prescribing pattern of drugs and compliance to standard treatment guidelines in patients of chronic Hepatitis B: a prospective observational study. *Int. J. Basic Clin. Pharmacol.* 12(4):509–514.doi:10.18203/2319-2003.ijbcp20231439.
- NICE. 2017. *Hepatitis B (chronic): diagnosis and management*. London: National Institute for Health and Care Excellence (NICE).
- Park JW, Kwak KM, Kim SE, Jang MK, Suk KT, Kim DJ, Park SH, Lee MS, Kim HS, Park CK. 2017. Comparison of the long-term efficacy between Entecavir and Tenofovir in treatment-naïve chronic Hepatitis B patients. *BMC Gastroenterol.* 17(1):1–9.doi:10.1186/s12876-017-0596-7.
- Poustchi H, George J, Esmaili S, Esna-Ashari F, Ardalan G, Sepanlou SG, Alavian SM. 2011. Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. *PLoS One.* 6(6):1–7.doi:10.1371/journal.pone.0021178.
- Roza YN, Oenzil F, Pertiwi D. 2017. Hubungan antara Merokok dan Tingkat Aktivitas Aminotransferase Serum pada Pegawai Kantor. *J. Kesehat. Andalas.* 6(2):409.doi:10.25077/jka.v6i2.713.
- Sabeena S, Ravishankar N. 2022. Horizontal Modes of Transmission of Hepatitis B Virus (HBV): A Systematic Review and Meta-Analysis. *Iran. J. Public Health.* 51(10):2181–2193.doi:10.18502/ijph.v51i10.10977.
- Sarin SK, Kumar M. 2008. Should chronic HBV infected patients with normal ALT treated: Debate. *Hepatol. Int.* 2(2):179–184.doi:10.1007/s12072-008-9065-2.
- Seley-Radtke KL, Yates MK. 2018. The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. *Antiviral Res.* 154(April):66–86.doi:10.1016/j.antiviral.2018.04.004.
- Sharma P. 2022. Value of Liver Function Tests in Cirrhosis. *J. Clin. Exp. Hepatol.* 12(3):948–964.doi:10.1016/j.jceh.2021.11.004.
- Song JE, Kim DY. 2016. Diagnosis of Hepatitis B. *Ann. Transl. Med.* 4(18).doi:10.21037/atm.2016.09.11.
- Survarachakan S, Prasad PJR, Naseem R, Pérez de Frutos J, Kumar RP, Langø T, Alaya Cheikh F, Elle OJ, Lindseth F. 2022. Deep learning for image-based liver analysis — A comprehensive review focusing on malignant lesions. *Artif. Intell. Med.* 130(June).doi:10.1016/j.artmed.2022.102331.
- Tan AKY, Loh KM, Ang LT. 2017. Evaluating the regenerative potential and functionality of human liver cells in mice. *Differentiation.* 98(September):25–34.doi:10.1016/j.diff.2017.09.003.
- Tatura SN., Sulistio M. 2023. Manifestasi Hepatik sebagai Prediktor Mortalitas

- COVID-19 pada Anak. *Med. Scope J.* 6(1):12–18.doi:10.35790/msj.v6i1.50323.
- Tripathi N, Mousa OY. 2023. Hepatitis B.
- Tsukuda S, Watashi K. 2020. Hepatitis B virus biology and life cycle. *Antiviral Res.* 182:104925.doi:10.1016/j.antiviral.2020.104925.
- Utami DP, Andriani A, Mardhia M, Novianry V, Zakiah M. 2021. EFEK HEPATOPROTEKTOR ANDROGRAPHOLIDE TERHADAP AKTIVITAS ALANIN AMINOTRANSFERASE DALAM SERUM Rattus norvegicus JANTAN GALUR WISTAR YANG DIINDUKSI KARBON TETRAKLORIDA. *J. Fitofarmaka Indones.* 8(1):7–11.doi:10.33096/jffi.v8i1.582.
- Vazi S, van Zyl S, Vorster -de Wet R, Tiloke C. 2023. Inflammatory properties of Tenofovir in human liver cells. *Heal. Sci. Rev.* 8(August):100114.doi:10.1016/j.hsr.2023.100114.
- Vernon H, Wehrle CJ, Alia VSK, Kasi A. 2022. Anatomy, Abdomen and Pelvis: Liver.
- Veronese P, Dodi I, Esposito S, Indolfi G. 2021. Prevention of vertical transmission of Hepatitis B virus infection. *World J. Gastroenterol.* 27(26):4182–4193.doi:10.3748/wjg.v27.i26.4182.
- Wang N, He S, Zheng Y, Wang L. 2023. Efficacy and safety of Tenofovir disoproxil fumarate versus Entecavir in the treatment of acute-on-chronic liver failure with Hepatitis B: a systematic review and meta-analysis. *BMC Gastroenterol.* 23(1):1–10.doi:10.1186/s12876-023-03024-7.
- Wani MA, Sodhi JS, Zargar SA, Yatoo GN, Shah A, Aziz SA, Geelani S, Haq I, Gulzar GM, Khan M. 2020. Entecavir is Safe and Effective in Long Term for the Treatment of Hepatitis B in Immunocompromised Children. *J. Clin. Exp. Hepatol.* 10(2):150–154.doi:10.1016/j.jceh.2019.04.002.
- Wassner C, Bradley N, Lee Y. 2020. A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide. *J. Int. Assoc. Provid. AIDS Care.* 19:1–10.doi:10.1177/2325958220919231.
- Watashi K, Urban S, Li W, Wakita T. 2014. NTCP and beyond: Opening the door to unveil Hepatitis B virus entry. *Int. J. Mol. Sci.* 15(2):2892–2905.doi:10.3390/ijms15022892.
- Wei S., Xie Q, Liao G, Al. E. 2024. Patients with chronic Hepatitis B who have persistently normal alanine aminotransferase or aged < 30 years may exhibit significant histologic damage. *MC Gastroenterol.* 24(120).
- Wei Sufang, Xie Q, Liao G, Chen H, Hu M, Lin X, Li H, Peng J. 2024. Patients with chronic Hepatitis B who have persistently normal alanine aminotransferase or aged < 30 years may exhibit significant histologic damage. *BMC Gastroenterol.* 24(1):1–10.doi:10.1186/s12876-024-03208-9.
- WHO. 2017. *Guidelines on Hepatitis B and C testing.* Volume ke-66. World Health Organization. Global Hepatitis Programme.

- Xu Q, Higgins T, Cembrowski GS. 2015. Limiting the testing of AST: A diagnostically nonspecific enzyme. *Am. J. Clin. Pathol.* 144(3):423–426.doi:10.1309/AJCPO47VAWYRIDHG.
- Zhao HJ, Hu YF, Han QJ, Zhang J. 2022. Innate and adaptive immune escape mechanisms of Hepatitis B virus. *World J. Gastroenterol.* 28(9):881–896.doi:10.3748/wjg.v28.i9.881.
- Zhou J, Wang F, Li L, Chen E. 2022. Expanding antiviral therapy indications for HBeAg-negative chronic Hepatitis B patients with normal ALT and positive HBV DNA. *Precis. Clin. Med.* 5(4).doi:10.1093/pcmedi/pbac030.
- Zhou L, Liu X, Ren F, Chen Y, Zheng S, Han Y, Zhao C, Duan Z. 2015. Changes in mitochondrial toxicity in peripheral blood mononuclear cells during four-year administration of Entecavir monotherapy in Chinese patients with chronic Hepatitis B. *Med. Sci. Monit.* 21:2058–2063.doi:10.12659/MSM.892937.

